| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445220 | European Journal of Cancer | 2013 | 9 Pages |
Abstract
Despite a very conservative definition of disease progression, panobinostat demonstrated activity with a manageable safety profile in bexarotene-exposed and -naïve CTCL patients. ClinicalTrials.gov Identifier: NCT00425555.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Madeleine Duvic, Reinhard Dummer, Jürgen C. Becker, Nicolas Poulalhon, Pablo Ortiz Romero, Maria Grazia Bernengo, Celeste Lebbé, Chalid Assaf, Margaret Squier, Denise Williams, Miriam Marshood, Feng Tai, H. Miles Prince,